REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Resources for you
and your patients.
Bristol Myers Squibb is dedicated to helping patients start and continue REVLIMID treatment until disease progression or unacceptable toxicity.
Resources and tools
for HCPs.

Explore resources to help
your patients with MM.

REVLIMID is only available through a restricted distribution program called the Lenalidomide REMS program.

REVLIMID is only available through
a select network of specialty pharmacies.

MM, multiple myeloma.
Reference: REVLIMID [package insert]. Summit, NJ: Celgene Corp.